The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma

The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR(+)CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliano, Sandy, Guyot, Mélanie, Grépin, Renaud, Pagès, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063157/
https://www.ncbi.nlm.nih.gov/pubmed/25050209
http://dx.doi.org/10.4161/onci.28399
_version_ 1782321757633380352
author Giuliano, Sandy
Guyot, Mélanie
Grépin, Renaud
Pagès, Gilles
author_facet Giuliano, Sandy
Guyot, Mélanie
Grépin, Renaud
Pagès, Gilles
author_sort Giuliano, Sandy
collection PubMed
description The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR(+)CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.
format Online
Article
Text
id pubmed-4063157
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40631572015-04-09 The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma Giuliano, Sandy Guyot, Mélanie Grépin, Renaud Pagès, Gilles Oncoimmunology Author's View The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR(+)CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target. Landes Bioscience 2014-04-09 /pmc/articles/PMC4063157/ /pubmed/25050209 http://dx.doi.org/10.4161/onci.28399 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Giuliano, Sandy
Guyot, Mélanie
Grépin, Renaud
Pagès, Gilles
The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
title The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
title_full The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
title_fullStr The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
title_full_unstemmed The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
title_short The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
title_sort elr(+)cxcl chemokines and their receptors cxcr1/cxcr2: a signaling axis and new target for the treatment of renal cell carcinoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063157/
https://www.ncbi.nlm.nih.gov/pubmed/25050209
http://dx.doi.org/10.4161/onci.28399
work_keys_str_mv AT giulianosandy theelrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma
AT guyotmelanie theelrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma
AT grepinrenaud theelrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma
AT pagesgilles theelrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma
AT giulianosandy elrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma
AT guyotmelanie elrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma
AT grepinrenaud elrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma
AT pagesgilles elrcxclchemokinesandtheirreceptorscxcr1cxcr2asignalingaxisandnewtargetforthetreatmentofrenalcellcarcinoma

Ejemplares similares